Danish Medicines Council recommends Genmab-developed sclerosis drug

On Thursday, the Danish Medicines Council announced that sclerosis drug Kesimpta, which is owned by Novartis but was developed by Genmab, can be used to treat Danes with relapsing remitting multiple sclerosis and high disease activity.

Photo: Jan Dagø/Jyllands-Posten/Ritzau Scanpix

In December, the Danish Medicines Council wasn’t convinced of the therapeutic advantages of Novartis’s sclerosis drug, Kesimpta.

Despite this, the council has now recommended the treatment for regular use in Danish hospitals – however, only for a subset of patients, those with relapsing remitting multiple sclerosis (RRMS) and high disease activity, the council reports in a press realease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs